Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The industry rank for Mach7 Technologies's 14-Day RSI or its related term are showing as below:
ASX:M7T's 14-Day RSI is ranked worse than 51.58% of 698
companies
in the Healthcare Providers & Services industry
Industry Median: 49.795
vs ASX:M7T: 56.24
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Mach7 Technologies 14-Day RSI Related Terms
ASX:M7T vs VEEV, BTSG, TEM: 14-Day RSI Comparison
For the Health Information Services subindustry, Mach7 Technologies's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mach7 Technologies 14-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Mach7 Technologies's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Mach7 Technologies's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mach7 Technologies (ASX:M7T) has a 14-Day RSI of 56.24 as of Jul. 15, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Mach7 Technologies and its competitors. According to the industry distribution chart, Mach7 Technologies ranks #360 out of 698 companies in the Healthcare Providers & Services industry, placing it in the top 51.6%.
Is Mach7 Technologies' 14-Day RSI too high?
Mach7 Technologies' current 14-Day RSI is 56.24. The Healthcare Providers & Services industry median 14-Day RSI is 49.80. Mach7 Technologies' value of 56.24 is 12.9% above this industry median. Based on the distribution chart, Mach7 Technologies ranks #360 out of 698 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Mach7 Technologies has a GF Score™ of 26/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mach7 Technologies' 14-Day RSI compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Mach7 Technologies ranks #360 out of 698 companies for 14-Day RSI. This places Mach7 Technologies in the lower half of its industry. The industry median 14-Day RSI is 49.80. Mach7 Technologies' value of 56.24 is 12.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Healthcare Providers & Services company?
The median 14-Day RSI among Healthcare Providers & Services companies is 49.80, based on 698 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mach7 Technologies's current 14-Day RSI of 56.24 is 12.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Mach7 Technologies and its competitors. For the Healthcare Providers & Services industry, the median 14-Day RSI is 49.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mach7 Technologies's current 14-Day RSI is 56.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mach7 Technologies stock overvalued right now?
Based on GuruFocus' analysis, Mach7 Technologies (ASX:M7T) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.84, compared to a current price of A$0.32 — trading 61.9% below its estimated fair value. The current 14-Day RSI is 56.24 and 12.9% above the Healthcare Providers & Services industry median of 49.80. Mach7 Technologies' overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Mach7 Technologies (ASX:M7T), the current 14-Day RSI is 56.24 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mach7 Technologies (ASX:M7T) Overvalued in 2026?
Based on GuruFocus' analysis, Mach7 Technologies stock appears to be undervalued.
The current stock price of A$0.32 is trading 61.9% below its estimated GF Value™ of A$0.84.
GuruFocus considers Mach7 Technologies to be Possible Value Trap.
Key valuation signals for ASX:M7T:
14-Day RSI: 56.24
GF Value™: A$0.84 vs. price of A$0.32 (61.9% below fair value)
Industry Position: 12.9% above the Healthcare Providers & Services median (#360 of 698)
No single metric tells the full story. See the ASX:M7T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mach7 Technologies Ltd is a healthcare software company focused on enterprise imaging infrastructure. The company's vendor neutral platform enables health systems to manage, access, and exchange medical imaging data across departments, sites, and vendors. It serves across North America, Asia-Pacific, and the Middle East, with deployments ranging from academic medical centres to multi-site health networks. A substantial part of revenue is derived in the form of Subscription revenue. Geographically, it derives a majority of its revenue from North America.
26GF Score
Get the complete analysis for ASX:M7T
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:M7T has been successfully added to your 
